The unresolved role of mitochondrial DNA in Parkinson’s disease: an overview of published studies, their limitations, and future prospects by Müller-Nedebock, Amica C et al.
The unresolved role of mitochondrial DNA in Parkinson’s 
disease: an overview of published studies, their limitations, 
and future prospects
Article  (Accepted Version)
http://sro.sussex.ac.uk
Müller-Nedebock, Amica C, Brennan, Rebecca R, Venter, Marianne, Pienaar, Ilse, van der 
Westhuizen, Francois H, Elson, Joanna L, Ross, Owen A and Bardien, Soraya (2019) The 
unresolved role of mitochondrial DNA in Parkinson’s disease: an overview of published studies, 
their limitations, and future prospects. Neurochemistry International. ISSN 0197-0186 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/84468/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
1 
 
The unresolved role of mitochondrial DNA in Parkinson’s disease: an overview 
of published studies, their limitations, and future prospects 
 
Amica C. Müller-Nedebock a, Rebecca R. Brennan b, Marianne Venter c, Ilse S. Pienaar d, e, 
Francois H. van der Westhuizen c, Joanna L. Elson c,f, Owen A. Ross b,g, h and Soraya 
Bardien a,* 
 
a Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, 
Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa 
b Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA 
c Human Metabolomics, North-West University, Potchefstroom, South Africa 
d School of Life Sciences, University of Sussex, Falmer, BN1 9PH, United Kingdom. 
e Centre for Neuroinflammation and Neurodegeneration, Imperial College London, London, 
United Kingdom. 
f Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom. 
g Department of Clinical Genomics, Mayo Clinic, Jacksonville, Florida, USA 
h School of Medicine and Medical Science, University College Dublin, Dublin, Ireland 
 
Abstract: 188 words 
Text (Including in-text citations, excluding conflicts of interest, Acknowledgements and 
References): 6539 words 
Number of Figures: 1 
Number of Tables: 3 
Supplementary Info: 3 Tables, 1 Figure 
 
* Corresponding author: 
Soraya Bardien, Ph.D. 
Division of Molecular Biology and Human Genetics,  
Department of Biomedical Sciences,  
Stellenbosch University, PO Box 241, Cape Town, 8000, South Africa 
Email address: sbardien@sun.ac.za. 
 
 
 
 
 
2 
 
ABSTRACT  
Parkinson’s disease (PD), a progressive neurodegenerative disorder, has long been associated 
with mitochondrial dysfunction in both sporadic and familial forms of the disease. 
Mitochondria are crucial for maintaining cellular homeostasis, and their dysfunction is 
detrimental to dopaminergic neurons. These neurons are highly dependent on mitochondrial 
adenosine triphosphate (ATP) and degenerate in PD. Mitochondria contain their own genomes 
(mtDNA). The role of mtDNA has been investigated in PD on the premise that it encodes vital 
components of the ATP-generating oxidative phosphorylation (OXPHOS) complexes and 
accumulates somatic variation with age. However, the association between mtDNA variation 
and PD remains controversial. Herein, we provide an overview of previously published studies 
on the role of inherited as well as somatic (acquired) mtDNA changes in PD including point 
mutations, deletions and depletion. We outline limitations of previous investigations and the 
difficulties associated with studying mtDNA, which have left its role unresolved in the context 
of PD. Lastly, we highlight the potential for further research in this field and provide 
suggestions for future studies. Overall, the mitochondrial genome is indispensable for proper 
cellular function and its contribution to PD requires further, more extensive investigation. 
 
Keywords: Parkinson’s disease, mitochondrial DNA, mitochondrial haplogroups, somatic 
mtDNA variation, homoplasmic mtDNA variation, mtDNA depletion  
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1. The mitochondrial genome 
Mitochondria are primarily responsible for generating adenosine triphosphate (ATP) via 
oxidative phosphorylation (OXPHOS). Besides nuclei, they are the only other cellular 
organelles harbouring their own genome (mtDNA). mtDNA is a compact (16,569 bp), circular, 
double-stranded genome, comprised of 37 genes including 13 which encode essential subunits 
of the OXPHOS enzymes (Figure 1)  [1]. More recently mtDNA has been reported to 
additionally encode two short open reading frames (sORFs) within the ribosomal RNA genes; 
MT-RNR1 and MT-RNR2 [2]. These sORFs can be translated into mitochondrial-derived 
peptides (MDPs) which have important functions including regulating nuclear gene expression 
in response to metabolic stress [3].    
Mitochondrial genomes differ to their nuclear counterparts with regards to their 
replication, repair and inheritance mechanisms. Unlike nuclear DNA (nDNA), mtDNA is 
primarily maternally inherited, although rare cases of biparental inheritance have recently been 
reported [4]. Moreover, it exists as multiple copies (known as polyploidy) within individual 
mitochondria. Hundreds to thousands of mtDNA copies can exist per mitochondria and thus 
per cell, depending on the energetic demand of the cell [5]. Compared to nDNA, mtDNA is 
highly susceptible to accumulating errors due to the lack of protective histones and its close 
proximity to damaging by-products of OXPHOS e.g. reactive oxygen species (ROS) [6]. In 
addition, reduced fidelity of the mtDNA polymerase, mtDNA polymerase gamma (POLG1), 
has been suggested to contribute to a higher mutational rate of mtDNA [7]. As a result, most 
individuals harbour low levels (<1%) of inherited and/or acquired mtDNA variants [8]. Most 
copies of mtDNA in a cell are identical, which is referred to as homoplasmy. A mix of both 
mutated and wild-type mtDNA is referred to as heteroplasmy. Levels of heteroplasmy can 
change over time through mechanisms of relaxed replication in postmitotic tissue and random 
segregation of mtDNA during cell division in mitotic tissues [9]. Although, the process of 
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mammalian mtDNA replication is not yet completely understood, mtDNA is known to replicate 
independently of the cell cycle - undergoing life-long replication in both proliferating and post-
mitotic cells [10]. Tissue-specific differences in mtDNA maintenance, replication, and 
expression exist [11] which, together with the unique features of mtDNA, particularly 
polyploidy and heteroplasmy, pose a significant challenge for studying their role in disease 
including Parkinson’s disease (PD).  
PD is a neurodegenerative movement disorder with a complex aetiology comprising both 
environmental and genetic factors. Progressive dopaminergic (DA) neuronal loss in the 
Substantia Nigra pars compacta (SNpc) is characteristic of PD, but pathological mechanisms 
are poorly understood. Despite decades of research and definite links to mitochondrial 
dysfunction in disease susceptibility and progression, the role of mtDNA in risk and 
pathogenesis of sporadic PD (sPD) remains equivocal. This review aims to appraise the 
literature to determine the reason(s) for this. We discuss results from published studies which 
have investigated mtDNA changes in PD and highlight inconsistencies between studies which 
have left the role of mtDNA in PD largely unresolved. We also draw attention to factors which 
complicate the study of mtDNA in PD and may have contributed to conflicting results. In doing 
so, we provide suggestions to guide and possibly improve future research in this field.   
2. Parkinson’s disease and mitochondrial dysfunction 
The DA neuronal loss in PD results in an array of classical motor symptoms including 
bradykinesia, tremor and rigidity [12]. These, together with various non-motor symptoms (e.g. 
depression, anxiety and insomnia), arising from the loss of additional neuronal populations, 
significantly compromise patients’ quality of life. A pathological hallmark of PD are Lewy 
bodies (LB); intracellular inclusions of the aggregate-prone, alpha-synuclein protein [13]. Only 
approximately 10% of cases have familial PD [14] and around 30% of these have monogenic 
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PD i.e. have mutations in nDNA-encoded genes [15]. Notably, most PD cases are sporadic and 
have an unknown aetiology of disease as well as an absence of a family history. However, both 
familial and sPD have been linked to mitochondrial dysfunction [16, 17]. 
Although the generation of ATP is the most recognised function of mitochondria, the 
organelles also participate in critical processes which help ensure cell viability, including lipid 
biosynthesis, calcium homeostasis and apoptosis and even play diverse roles in immune 
response [18, 19]. Mitochondrial dysfunction therefore impinges on a wide spectrum of cellular 
functions. This dysfunction is multifactorial in origin and can arise from impaired 
mitochondrial biogenesis, altered mitochondrial dynamics (e.g. fission and fusion), impaired 
mitochondrial quality control (mitophagy), compromised OXPHOS and calcium imbalances 
[20].   
Early evidence that mitochondrial dysfunction may play a central role in sPD 
pathogenesis resulted from the unintentional exposure of humans to the drug 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridin (MPTP), specifically its active derivative MPP+, causing 
parkinsonian symptoms [21, 22]. Primate models subsequently reported SNpc DA cell loss and 
other parkinsonism symptoms including akinesia, tremor and rigidity in monkeys treated with 
a form of MPTP [23]. Similarly, MPP+  mouse models exhibited DA neuronal loss [24, 25] 
and showed that MPP+ inhibits complex I activity, thereby interfering with OXPHOS [26, 27].  
As such, an energy crisis was suggested as an important mechanism underlying neuronal 
degeneration leading to PD symptoms [26, 27]. Subsequently, in the late 1980’s and early 
1990’s, defects of complex I were observed in various tissues of sPD patients, including 
skeletal muscle [28-32], the SNpc [33, 34] and platelets [35-38]. As a consequence of these 
initial studies, it was hypothesized that the observed complex I defect may be derived via the 
mitochondrial genome [17]. Moreover, genes linked to early-onset forms of PD (e.g. PINK1, 
PRKN and DJ-1), encode proteins which participate in- or mediate some form of mitochondrial 
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function, regulation or quality control [20]. For instance, as reviewed elsewhere [39], the 
proteins PINK1 and Parkin are involved in mitophagy, consequently, loss of function mutations 
in nDNA encoding these proteins affect mitochondrial biogenesis and induction of autophagy.  
3. Early evidence for mtDNA involvement in PD from cybrids 
In addition to nDNA mutations contributing to familial PD onset, mtDNA variation has been 
linked to sPD, as demonstrated through cybrid (cytoplasmic hybrid) cell line studies (Table 1) 
[40].  Briefly, ρ0 cells which are devoid of mtDNA but contain identical nDNA, are fused with 
mtDNA-containing platelets from either PD patients or controls. Following multiple cellular 
replication cycles, the cybrids generated share the same environmental and nDNA background, 
differing only with regards to their mitochondrial genomes [41, 42]. Therefore, differences 
observed between cell lines with differing mtDNA content, from either a patient or control, are 
thought to be solely attributable to the mtDNA itself [41-43]. As a result, p0 cybrid cells have 
provided a useful tool to investigate the role of mtDNA in cellular health and in disease. 
Albeit an effective model to study mtDNA background in vitro, cybrid studies have limitations 
which contribute to discrepancies between studies. One of the most notable is the frequent use 
of tumour cell lines exhibiting aneuploidy or other forms of nuclear genomic instability [44]. 
Despite potential limitations, sPD cybrid studies have consistently provided insight into the 
role which mtDNA background has on mitochondrial morphology and function between cell 
lines from patients and controls (Table 1).   
Notably, emerging evidence implicates mitochondrial genomes in modulating nuclear gene 
expression by means of signalling pathways [45-47]. These include the integrated stress 
response, retrograde (mitochondria-nucleus) communication, proteostasis regulation and 
mitonuclear feedback signalling [48]. With mitochondrial biogenesis, maintenance and other 
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mitochondrial processes heavily depending on nDNA gene expression [49], mtDNA may 
influence these processes and could for instance account for variable biogenesis between sPD 
cybrids with differing mtDNA donors [50].  
Importantly, sPD cybrids have exhibited several features of mitochondrial dysfunction 
including decreased complex I activity, increased ROS, morphologically abnormal 
mitochondria and decreased maximum respiratory capacity, linking mtDNA to sPD (Table 1). 
These findings all highlight that mtDNA can substantially influence important mitochondrial 
processes and physiology. Consequently, cybrid studies spawned investigations aimed at 
identifying mtDNA variation which could account for mitochondrial abnormalities observed 
in sPD cybrids. 
4. Studies investigating homoplasmic mtDNA variation  
4.1 Early mtDNA sequencing studies 
In the 1990’s and early 2000’s, a few studies sequenced the complex I genes of PD patients 
and controls to identify possible mtDNA variants associated with the disorder [51-55]. 
Standard Sanger sequencing techniques available during this time were primarily limited to 
identifying homoplasmic or high-frequency heteroplasmic variants [56]. A few studies 
sequenced whole mtDNA [57, 58], whilst others sequenced all of the mtDNA tRNA [54, 59, 
60] and rRNA genes [60]. Furthermore, some employed restriction fragment length 
polymorphism (RFLP) methods to investigate whether certain mtDNA variants (e.g. 
m.3397A>G in MT-ND1) associate with PD [61, 62].  
A handful of studies identified ‘novel’ variants in PD patients [52, 53, 59, 60] and 
reported variants at an increased frequency in cases compared to controls [55, 62]. However, 
their findings may have been coincidental. This is because the sample sizes were often too 
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small to draw statistically-powerful conclusions. Additionally, sequencing was still in its 
infancy, making it more likely to identify false positives due to the limited number of known 
variants which had been reported. In support of this statement, most of these ‘novel’ variants 
have now been reported in individuals without PD on the MITOMAP database [63]; 
https://www.mitomap.org/MITOMAP), although not at high frequencies (Supplementary 
Table 1). Based on these early sequencing studies, no homoplasmic nor high-frequency 
heteroplasmic mtDNA variants were conclusively implicated in PD pathogenesis or risk.  
4.2 Haplogroup association studies  
The sequential accumulation of new variation in maternal lineages over thousands of years has 
generated stable mtDNA sequence variation which is homoplasmic. Subsets of such stable 
mtDNA variation define haplogroups which are primarily restricted to particular populations 
and geographic areas [64]. Details of variants which define individual mtDNA haplogroups are 
recorded on PhyloTree [65]; http://www.phylotree.org/).  
Over the past two decades, the associations between mtDNA haplogroups and PD risk 
have been extensively studied using the ‘haplogroup association approach’, particularly in 
populations of European ancestry (Table 2 and Supplementary Table 2). This approach 
associates haplogroups with a disease phenotype and suggests that one or more common 
population variants may modify disease risk. As a result of these studies, multiple European 
haplogroups including J, K, U, and some super-haplogroups (e.g. UK and JT) have been 
associated with a reduced risk of PD [66-73]. However, a number of additional studies were 
unable to replicate these findings and found no significant association between PD and 
haplogroups or common haplogroup variants [71, 74-78] (Table 2 and Supplementary Table 
2). For instance, Mehta et. al [71] were unable to replicate previous associations between PD 
risk and haplogroups J and K in a large Australian cohort of European ancestry. Additionally, 
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Van Der Walt et. al [73] and Huerta et. al [75] identified the MT-ND3 single nucleotide 
polymorphism (SNP) m.10398A>G to be protective against PD, whilst multiple other studies 
could not replicate this finding [66, 68, 69, 76]. Asian haplogroup association studies have also 
produced somewhat inconsistent results (Table 2 and Supplementary Table 2). For instance, 
although Wu et. al [79] and Liou et. al [80] both reported the Asian haplogroup B5 to be 
protective against PD, studies done by Chen et. al [81] and Chen et. al [82] reported no 
significant overall association between any of the common Asian haplogroups and PD risk.  
Overall, the evident variability in results and lack of reproducibility across haplogroup studies 
has made it difficult to conclude whether common mtDNA population variants contribute to 
PD risk.  
4.2.1 Limitations of past haplogroup association studies and possible sources of 
inter-study variability  
To improve the design of future studies, it is important to identify all possible factors which 
are introducing variability into, and between studies in order to limit false positive or erroneous 
findings. In the following section we therefore highlight possible methodological concerns 
which may contribute to discrepancies between study findings and should be addressed in 
future work.  
Population stratification 
mtDNA haplogroup association studies are often confounded by high levels of population 
stratification, referring to systematic differences in allele frequencies between subpopulations 
in a population, due to different ancestry [83]. This is because mtDNA itself is more prone to 
population substructure than nDNA, given that its effective population size is four times 
smaller than that of nDNA due to its uni-parental inheritance. Even when cases and controls 
are well matched in other regards (e.g. age, sex) substructure can be a confounding factor which 
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may result in false positives.  A study done by Otaegui et. al [84] with a cohort of Spanish PD 
patients, from different origins (Basque and non-Basque), and non-Basque controls, 
highlighted the importance of conducting case-control association studies in ethnically 
homogeneous populations (Table 2 and Supplementary Table 2). The authors found no 
association between PD and the m.10398A>G SNP (P = 0.088) when comparing all cases to 
controls but observed a significant overrepresentation of this SNP specifically in PD patients 
of Basque origin when compared to the non-Basque control population (P = 0.0221). 
Replication cohorts and multiple testing  
Several case-control association studies, including some of the ‘PD haplogroup’ studies listed 
in Table 2, lack replication cohorts [85]. Such replication cohorts or even a second control 
group (e.g. as used by Ghezzi et. al [68], Pyle et. al [72] and Chen et. al [82]) can be useful for 
detecting population substructure which affects the validity of results if not taken into 
consideration [86].  
Additionally, multiple PD haplogroup association studies failed to correct their P-values/ 
significance levels for multiple testing (Table 2 and Supplementary Table 2). This may also 
have resulted in false positive findings [87]. 
Power  
Samuels et. al [88] demonstrated that when using the haplogroup association hypothesis, very 
large sample sizes of cases and controls are necessary in order to reliably detect an association 
between haplogroups and complex human disease. To demonstrate this, the authors gave the 
example that studies with 500 cases and 500 controls have 90% power to detect a greater than 
35% change in the frequency of the common haplogroup H. Therefore, several of the PD 
haplogroup studies are underpowered (Table 2 and Supplementary Table 2). Additionally, such 
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underpowered haplogroup association studies are frequently analysed in ways which violate 
the assumptions of the statistical tests used, thereby inflating Type 1 error [85].  
Pseudo-haplogroups   
Pseudo-haplogroups are usually composed of low frequency haplogroups present in the study 
cohort, clustered together in ways which cannot be justified by phylogenetic knowledge [74]. 
Interestingly, this artificial clustering of haplogroups is commonly observed in neurological 
association studies including those done by Pyle et. al [72], Ghezzi et. al [68], Gaweda-
Walerych et. al [66] and Latsoudis et. al [76] on PD risk. The creation of such pseudo-
haplogroups results in erroneous inferences and false positive findings [74]. This is because 
pseudo-haplogroups are not biologically meaningful; they do not share a set of variants 
characterising an exclusive phylogenetic branch. To demonstrate this, Fachal et. al [74] 
artificially merged haplogroups U and V of a migraine cohort from Cantabria.  This resulted in 
the UV pseudo-haplogroup being significantly associated with migraines (P = 0.0268) even 
though it did not make phylogenetic sense. Thus, emphasising the risk of false associations 
when pseudo-haplogroups are used. 
In summary, PD haplogroup studies have reported inconsistent findings. Evidently, there are 
many methodological concerns around haplogroup studies which may have influenced the 
findings of past studies. These concerns should carefully be addressed in future. 
5.  Somatic mtDNA changes in PD 
Somatic mtDNA variation, including point mutations and deletions, accumulate over time in 
post-mitotic tissue, including the ageing human brain [89-91]. This gives rise to a mixed 
population of mutant and wild-type mtDNA molecules i.e. heteroplasmy.  The acquired 
variants may additionally clonally expand in individual cells through relaxed replication and 
random intracellular drift [92]. During relaxed replication, mtDNA molecules are randomly 
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selected for replication. Thus, the proportion of mtDNA heteroplasmy in a cell can significantly 
increase over time if mutant mtDNA molecules are replicated more frequently by chance than 
the wild-type mitochondrial genomes [92]. When the proportion of mutant mtDNA molecules 
with harmful mtDNA changes exceeds a critical threshold level, a cellular defect in OXPHOS 
will arise [93]. Consequently, a number of studies have investigated high levels of 
heteroplasmic mtDNA point mutations and mtDNA deletions in the post-mortem brain tissue 
of PD patients. Both deletions and point mutations in these studies were considered somatic 
rather than germline. 
5.1 Somatic mtDNA point mutations and deletions 
With the advent of sequencing technologies sensitive enough to detect low-level 
heteroplasmies (< 10%), a handful of studies sequenced mtDNA in PD cases and controls 
extracted from post-mortem brains (Table 3 and Supplementary Table 3). They hypothesised 
that multiple, individually rare mtDNA point mutations in either the entire mitochondrial 
genome, or subset of mtDNA genes, could collectively constitute a high variant burden in the 
brains of PD patients. This burden would ultimately lead to neuronal loss. However, only two 
studies reported significantly higher burdens of point mutations in the brains of PD cases 
compared to controls [94, 95]. Others reported no significant difference between case and 
control groups (Table 3 and Supplementary Table 3) [51, 96-98].  
In addition, acquired mtDNA deletions have also been suggested to play an important 
part in the selective neuronal loss in the ageing and PD brain [90, 99-101]. Mechanisms, such 
as breakpoints in tandem repeats of mtDNA or replication errors [102] give rise to these 
deletions [100, 101]. Notably, DA metabolism has been shown to drive the generation of 
mtDNA deletions in in vitro and in vivo models [103]. DA is readily oxidised, leading to ROS 
and neurotoxic quinone production [104]. ROS, such as H2O2, have been shown to cause single 
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and double stranded breaks in mtDNA in vitro [105]. As such, SNpc DA neurons appear to be 
particularly susceptible to accumulation of mtDNA deletions and most of these deletions are 
located between the heavy and light strand origins of replication (the major arc; Figure 1) [106].  
The ‘common deletion’ is a 4,977-base-pair deletion located between the MT-ATP8 and 
MT-ND5 genes, spanning four genes coding for complex I (MT-ND3, MT-ND4, MT-ND4L and 
MT-ND5) (Figure 1). It is thought to bring about a complex I defect, thus an energy crisis [107]. 
The frequency of mtDNA carrying this deletion in PD cases compared to controls has been 
investigated using Southern blotting, competitive- and kinetic-PCR techniques as well as in 
situ hybridisation techniques [107-111]. Despite two studies reporting a greater burden of this 
deletion in patients compared to controls [107, 111], others could not replicate these findings 
[108-110]. Instead, they reported no difference between cases and controls, suggesting that the 
common deletion may be a result of the natural ageing process rather than disease pathogenesis. 
Gu et. al [112] later reported that the number of mtDNA deletions (not limited to the common 
deletion) was increased significantly the SN homogenate of PD patients compared to age-
matched controls, patients with multiple system atrophy, Dementia with Lewy Bodies, and 
those with Alzheimer’s disease.  
Additional studies compared the total burden of mtDNA carrying deletions in the major 
arc, between brains of PD cases and controls using quantitative PCR (qPCR) [90, 96, 113, 114]. 
Such qPCR methods typically measure the ratio of a gene not commonly deleted (e.g. MT-
ND1) in mtDNA to one which is frequently deleted (e.g. MT-ND4) using either relative or 
absolute quantification methods. The latter requiring a standard curve. Two studies reported 
significantly higher burdens of mtDNA deletions in individual DA SNpc (P = 0.004) [96] and 
pedunculopontine cholinergic neurons (P < 1×10-4) [114] of PD cases compared to controls. 
The others reported no significant differences in deletion levels between SN neurons of cases 
and aged control groups [90, 113]. 
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Based on the evidence outlined above, it is reasonable to argue for or against a role of somatic 
point mutations and/or deletions in PD pathogenesis. However, variability between study 
designs (but also small sample sizes) makes it difficult to compare findings across studies and 
makes it challenging to draw a reliable conclusion regarding the contribution of somatic 
mtDNA deletions and point mutations to PD.  
5.2 Changes in mtDNA copy number 
In addition to possible point mutations and deletions in mtDNA molecules, mtDNA depletion 
should also be considered as a possible predisposing factor for PD. The importance of adequate 
mtDNA in cells is highlighted by mtDNA depletion syndromes – a group of autosomal 
recessive disorders characterised by severe mtDNA depletion which results in impaired energy 
production [115]. Since mtDNA encodes essential OXPHOS complex components, a sufficient 
amount of mtDNA is required for the production of these OXPHOS subunits and to manage 
cellular energy demands [116]. Therefore, there has also been growing interest in 
understanding mtDNA levels (mtDNA copy number) in PD.  
Frequently, studies investigating mtDNA copy number have used qPCR methods to 
quantify the ratio of MT-ND1 to a nuclear house-keeping gene. Recent studies have reported 
significant differences in mtDNA copy number values between PD patients and controls in the 
SN, with lower mtDNA copy numbers observed in the patients [96, 113, 117].  Notably, in one 
study mtDNA copy number in DA neurons was observed to increase with age in controls [96].  
Therefore, despite the age-related accumulation of mtDNA deletions, the pool of wild-type 
mtDNA was maintained. In contrast to the controls, no compensatory increase in mtDNA copy 
number was observed in patients, resulting in relative depletion of wild-type mtDNA in the 
SNpc. This was suggested to ultimately result in respiratory deficiency and neuronal loss. Bury 
et. al [114], who observed increased levels of both mtDNA deletions and mtDNA copy number 
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in pedunculopontine cholinergic neurons of PD cases compared to controls, suggested that 
different neurochemical cell types and brain regions in PD patients may differ in response to 
mtDNA deletion accumulation. However, reasons for the lack of possible compensatory 
mechanisms in the SNpc of the PD brain remain unclear. Hence, further research is warranted 
on how mtDNA levels are regulated in different cell-types. 
mtDNA depletion has also been recognised as a potential biomarker for PD detection 
because significant reductions in mtDNA copy number have not only been observed in the SN 
of PD patients [96, 113, 117] but also in peripheral blood [117, 118] and cerebrospinal fluid 
[119]. Overall, reports on mtDNA depletion in PD appear promising, although further research 
in this field is required, particularly with regards to the mechanisms underlying mtDNA 
depletion and its utility as a biomarker. 
5.3 Challenges of studying somatic mtDNA changes in PD 
Studying acquired mtDNA changes in PD is particularly challenging, rendering the role of 
mtDNA in PD unresolved. Many factors can substantially influence study findings and can 
contribute to inconsistent reports such as those detailed above. In the following section we 
highlight important methodological and biological factors to consider when studying somatic 
mtDNA changes in PD case-control studies.  
Techniques and technologies 
Technologically, many well-established molecular techniques used to study nDNA variation 
may not be suitable for the study of mtDNA. A review by Moraes et. al [120] drew attention 
to techniques including Southern blotting, PCR amplification, and RFLP, and reviewed their 
respective advantages and disadvantages when analysing heteroplasmic mtDNA point 
mutations and deletions. The authors highlighted that these techniques can yield misinterpreted 
results for mtDNA given the genome’s unique properties of heteroplasmy and polyploidy. 
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Thus, the use of Southern blotting and different PCR techniques in earlier mtDNA deletion 
studies could account for inconsistent findings. For instance, Ikebe et. al [107] and Ozawa et. 
al [111], employed PCR and kinetic-PCR techniques respectively, and reported significantly 
higher mtDNA common deletion levels in cases compared than controls. In contrast Mann et. 
al [109] and Kösel et. al [108] who employed Southern blotting and competitive PCR 
techniques respectively found no significant increase of this deletion in cases compared to 
controls. Newer techniques used to quantify mtDNA deletions also have disadvantages. For 
instance, the relative quantification of levels of MT-ND1 to MT-ND4 fails to quantify rarer 
mtDNA deletions which extend into the minor arc and may not reflect the true extent of deleted 
mtDNA.  
Moreover, the ability to confidently detect and quantify low levels of point mutation 
heteroplasmies in mtDNA varies between sequencing technologies [121, 122]. Some 
technologies such as Sanger sequencing are not sensitive enough to detect individually-rare 
mtDNA variants below 15% heteroplasmy, thereby potentially underestimating heteroplasmic 
variant levels [123]. Others, such as post-PCR cloning strategies, are at risk of over-estimating 
heteroplasmic variant loads because of DNA polymerase enzyme transcriptional errors which 
are indistinguishable from true variants [122]. As a result, sequencing data generated using 
such technologies may not be truly representative of the heteroplasmic mtDNA levels in a 
sample and have likely contributed to some inconsistent findings between published studies 
(Table 3).  
When employing newer, next generation sequencing approaches (NGS), sequencing 
depth affects the level of heteroplasmy detected [124]. This level varies between NGS 
approaches. Ultra-deep sequencing of the mtDNA, with a depth of several tens of thousands is 
required to confidently detect very low levels of heteroplasmies (~1-10%). Additionally, 
technical artefacts and sequencing errors need to be controlled for in NGS to achieve accuracy 
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of quantification and detection specificity [124]. To control for these errors and artefacts, NGS 
studies should integrate effective quality-control criteria. Web-based servers such as mtDNA-
Server (https://mtdna-server.uibk.ac.at) are available specifically for the analysis of mtDNA 
NGS data. The workflow includes several quality control metrics, identification of artefacts 
and contamination, heteroplasmy detection, as well as variant annotation [125]. The use of such 
servers could aid in standardising heteroplasmy detection and quantification across studies. 
Moreover, as mentioned, mtDNA in post-mitotic tissue is likely to accumulate deletions 
with age [99]. Consequently, mtDNA amplification in aged, post-mortem brains, prior to 
sequencing, could also influence results of sequencing studies. For instance, amplifying 
mtDNA in two fragments which overlap the deletion-prone major arc may result in mtDNA 
sequence data which was unrepresentative of the entire mtDNA data population. This is 
because mtDNA carrying deletions in the primer binding sites may not be amplified given that 
primers may not bind and not amplify the mtDNA effectively.  
Finally, predicting the functional impact of mtDNA variants in sequencing studies is 
important. This is because the levels of variation accumulating with age in controls could be 
similar to those accumulating in PD patients but may collectively be less pathogenic. It should 
be stressed that studies should use in silico tools specifically developed for mtDNA variation 
since those developed for nDNA may not be suitable to predict the pathogenicity of mtDNA 
variants [126]. Examples of mtDNA tools include APOGEE [127], MToolBox [128] and 
MitoTIP [129]. Tools like eKLIPse [130] are also available for identifying and quantifying 
mtDNA deletions (and other rearrangements) and should be considered for future studies. 
 Tissue and brain region 
There are tissue specific differences in mtDNA heteroplasmy accumulation [131] and ‘hot-
spot’ regions of heteroplasmy accumulation in mtDNA [132, 133]. As a result, the brain tissue 
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and mtDNA region selected for examination in post-mortem studies will influence results. As 
detailed in Table 3, published studies did not all sequence the same mtDNA region, nor 
examined DNA from the same brain region, which could explain conflicting results. Although 
multiple regions of the brain are affected in PD, the loss of DA neurons in the pathologically 
affected SNpc is the most extensive [134]. The SNpc, in comparison to other brain regions, 
may therefore be expected to show the greatest difference in mtDNA changes between cases 
and controls, should such changes contribute to neuronal loss in PD, as hypothesised. 
Depending on cellular energy demand, the number of mitochondria per cell and the 
copies of mtDNA per mitochondria can differ substantially between cell types in whole tissue 
[135]. As such, whole blood samples frequently used for mtDNA copy number assays may be 
biased by cellular composition. For instance, samples with more granulocytes than 
lymphocytes, may show lower mtDNA copy numbers than ones with a higher proportion of 
lymphocytes [136]. This is because granulocytes have been observed to have fewer 
mitochondria, and thus less mtDNA, than lymphocytes [136]. 
Moreover, mtDNA deletion and point mutation studies using tissue homogenate rather 
than single cells are also likely biased by the cellular composition of samples. mtDNA changes 
identified in tissue homogenate may not reflect the true changes in mtDNA between cases and 
controls. For instance, although both glial cells and neurons acquire mtDNA variants, somatic 
variants accumulate preferentially in neurons [137]. In support of this, Lin et. al [95] reported 
that overall levels of mtDNA point mutations were similar in SN glia of early PD and incidental 
Lewy body disease (ILBD) cases (Braak stage 3) and controls. However, they were 
significantly elevated in the single SN neurons of early PD + ILBD cases compared to controls 
(Table 3). As such, a homogenised tissue sample consisting of predominantly glial cells may 
have less mtDNA variation than one which consists predominantly of neuronal cells. Given 
that post-mortem brains of PD patients typically represent advanced stages of the disease and 
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that up to 98% of DA SNpc neurons can be lost during advanced PD [138], mtDNA molecules 
examined in PD brain homogenate most likely originate primarily from surrounding glial cells.  
Moreover, although studying individual cells is advantageous to avoid the bias of tissue 
composition, it can still be problematic. The surviving neurons in post-mortem brain tissue of 
patients with advanced PD may have accumulated fewer somatic mtDNA changes allowing 
the neurons to persist. On the other hand, already degenerated neurons are likely to have 
accumulated very high levels of detrimental, somatic errors. Consequently, the surviving 
neurons of late-stage PD may not differ significantly to those of aged controls with regards to 
mtDNA changes. Therefore, the pathological stage of disease of the patients from whom the 
tissue samples originated needs to be accounted for [139]. Examining neurons from early-stage 
(~ Braak stage 3) post-mortem tissue may be the best strategy. 
6. Future studies  
To date the role of mtDNA in PD has not yet been resolved largely due to the difficulty of 
studying mtDNA variation but also ‘poor’ study design. However, there is potential for 
improvement in this field. Future studies need to consider the limitations of previous studies 
and the challenges associated with studying mtDNA to improve future study designs. For 
instance, small sample sizes are a significant limitation and can be overcome with new 
collaborations [140]. Studies should also consider using newer, more standardised approaches, 
such as the variant load approach, which potentially circumvent pitfalls of past investigations. 
Alternatively, future studies could branch into studying nDNA variation in conjunction with 
mtDNA changes. These and additional options are discussed below. 
6.1  Homoplasmic mtDNA variation: considering functional studies and the 
collective role of rare population variants  
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Several authors have highlighted the methodological deficiencies of haplogroup association 
studies, some of which have also been outlined in this paper [74, 141, 142]. Yet, the methods 
used in these studies have not changed significantly over the past 20 years.  
The current ‘haplogroup association’ approach uses only a few mtDNA SNPs. This 
makes it a cheap and relatively simple method to perform, that doesn’t require more high 
throughput technologies such as whole exome or complete mitochondrial genome sequencing 
and avoids complex bioinformatics analyses. We suggest that results from future haplogroup 
studies should ideally be validated using functional investigations (e.g. cybrid or histochemical 
studies) [143] although this might be challenging given that association genetics is based on 
very subtle effects. Nonetheless, additional work assessing mitochondrial homeostasis 
regulation and function (e.g. measuring ROS production, cellular respiration etc.) can provide 
functional evidence to support the genetic associations made. For example, Liou et. al [80] 
were able to validate their findings using cybrids. In their study, cybrid results revealed that 
the B5 haplogroup cybrid, harbouring the m.8584G>A/m.10398A>G variants showed more 
resistance to rotenone than the B4 cybrid lacking these variants. Briefly, rotenone is a pesticide 
and a complex I inhibitor, implicated in PD pathogenesis [144]. Furthermore, low ROS 
production and low apoptosis rates were also observed in the B5 cybrid [80], supporting the 
hypothesis that the B5 haplogroup variants have a protective effect against PD. Another recent 
study reported that haplogroup K1 increased mtDNA copy number and demonstrated a 
resistance to rotenone [145]. These findings support haplogroup studies which associated 
haplogroup K with a PD protective effect [68, 69], and highlight the value of such studies. 
Although haplogroup association studies can be improved with such additional functional 
work, or by using replication cohorts, correcting for multiple testing, and avoiding pseudo-
haplogroup construction, the current discrepancies between studies also highlight the need for 
newer and more standardised models.  
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Future studies should study homoplasmic, rare population variants which are mildly deleterious 
and could collectively contribute to disease risk in an individual, instead of only investigating 
haplogroup-defining variants in PD risk. This hypothesis, known as the variant load hypothesis, 
distances itself from the study of haplogroups [146]. The most up-to-date version of the variant 
load hypothesis excludes variants predicted to be likely benign from the analysis, as many of 
these variants are common polymorphisms. Such common variants are more likely to be 
subject to population stratification, thus if left in the analysis they might be the cause of false 
positive associations. The variant load approach additionally condenses the likely impact of an 
individual’s mtDNA variation into a numerical value on a continuous scale rather than in the 
form of a letter as done in haplogroup studies. Consequently, more powerful parametric 
statistics can be applied and fewer comparisons are needed, thus granting this approach greater 
statistical power with smaller sample sizes than the traditional haplogroup association method 
[147]. For instance, a recent study with a total sample size of 82 employed the variant load 
approach to investigate the role of mtDNA in oxidative stress and inflammation [148]. This 
study had 80% power to detect a correlation (with moderate effect size) between markers of 
oxidative stress and inflammation and variant loads. Given the decreasing cost of NGS and the 
growing availability of pipelines which simplify mtDNA data analyses, whole mtDNA 
sequencing data can be used to test the variant load hypothesis.  
6.2 Somatic mtDNA variation and mtDNA depletion 
Studying the role of somatic mtDNA variation in PD is challenging especially since the 
availability of PD post-mortem brains is limited and the pathological stage of disease may vary. 
Moreover, not all molecular techniques used to study nDNA variation are suitable for mtDNA 
given the unique features of mitochondrial genomes (polyploidy and heteroplasmy). Future 
studies should therefore carefully consider which molecular techniques would be most suitable 
for the purpose of their investigation to ensure results are reliable. Moreover, somatic mtDNA 
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studies should correct for tissue cellular composition bias where possible. A combination of 
the strategies employed in the herein reviewed studies could be best to study somatic mtDNA 
variation in PD, particularly mtDNA point mutations. For instance, ultra-deep sequencing 
technologies could be used to sequence mtDNA molecules of individual, early-stage PD and 
control SNpc neurons.   
mtDNA depletion in PD is an emerging biomarker of disease pathology and may be more 
promising to understand PD than somatic mtDNA variation given that mtDNA depletion 
studies have reported few discrepancies [96, 113, 117-119]. We suggest future studies should 
try to replicate these reports of mtDNA depletion in PD but also correct for cellular composition 
when possible, to make results more reliable and reproducible [149]. 
Future studies should also place greater focus on studying nDNA variation, in combination 
with mtDNA changes, which may underlie potentially high mtDNA variant burdens in PD 
brains, and/or mtDNA depletion. For instance, Gui et. al [118] reported that PD patients with 
a particular POLG1 genotype in combination with additional POLG1 variants, had 
significantly lower numbers of mtDNA than those without such variants. This suggested that 
POLG1 variation may contribute to mtDNA depletion in PD cases. POLG1 encodes a subunit 
of the DNA polymerase which replicates mtDNA. mtDNA mutator mice with mutations in 
nDNA encoding mtDNA replication components, including Polg1, have additionally 
demonstrated an accelerated accumulation of mtDNA point mutations and deletions, 
highlighting a potential role for nDNA underlying mtDNA changes [150-153]. As a result of 
these mtDNA changes, the mutator mice demonstrate a progressive respiratory chain 
dysfunction as seen in PD patients and premature aging phenotypes (e.g. hair loss, osteoporosis, 
and progressive hearing loss) [151]. These studies again implicate somatic mtDNA changes, 
resulting from nDNA mutations, in PD which has been hypothesised to be a form of accelerated 
aging [154, 155]. Mitochondrial transcription factor A (TFAM) is an essential DNA-binding 
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protein required for transcription and maintenance of mtDNA. Knockout mice with a deleted 
Tfam gene demonstrate a respiratory chain deficiency and reduced mtDNA expression in DA 
neurons [156]. These mice also exhibit parkinsonism typical phenotypes including progressive 
motor function impairment and DA neuronal loss [156] implicating defective mtDNA 
maintenance in PD, brought about by nDNA changes. Notably, components of the nDNA-
encoded, mtDNA replication machinery including mitochondrial genome maintenance 
exonuclease 1 (MGME1), POLG1, and mtDNA replicative helicase (TWINKLE) have recently 
been implicated in degradation of damaged mtDNA [157]. Thus, nDNA variation in genes 
encoding these factors is of particular interest for further study given their dual role mtDNA 
synthesis and degradation [102].  
6.3 Mitochondrial-derived peptides (MDPs) 
Recently, MDPs, encoded as sORFs, in mtDNA have been identified as important regulatory 
peptides of metabolic activity and stress response [2, 158, 159]. The discovery of MDPs 
underscores the potential existence of more sORFs hidden in mtDNA. Recent findings have 
implicated the mitochondrial open reading frame of the 12S rRNA-c (MOTS-c), a 16-amino-
acid MDP encoded within the MT-RNR1 gene, in the regulation of nuclear gene expression in 
response to metabolic stress [3]. These findings suggest that nuclear and mitochondrial 
genomes cross regulate each other but they also highlight the potential of MDP involvement in 
disease [160].  Further work needs to be conducted to better understand the role of MDPs and 
the mechanisms regulating their expression in PD.  
7. Concluding remarks 
PD is an immensely complex disorder of multifactorial origin, but one with clear links to 
mitochondria and their genomes. Early evidence directly implicates mtDNA of sPD patients in 
altering mitochondrial structure and function. However, despite a multitude of studies 
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investigating mtDNA in PD, the contribution of the mitochondrial genome to this disorder 
remains elusive. 
To date, studies investigating homoplasmic and heteroplasmic mtDNA changes in PD have 
produced conflicting results. In almost all of these studies, low statistical power resulting from 
small sample sizes is a significant limitation, which likely contributed to some discrepant 
findings. Most mtDNA haplogroup association studies additionally suffered from 
methodological deficiencies (e.g. population stratification, lack of- replication cohorts and 
correction for multiple testing) which could primarily contribute to such discrepancies. On the 
other hand, innate difficulties of studying somatic mtDNA changes (e.g. heteroplasmy and 
tissue specific differences in mtDNA) along with different methodological techniques applied 
have produced conflicting results in somatic mtDNA studies which either provide evidence for 
or against a role of somatic mtDNA changes in PD.  
Consequently, a role for the involvement of mtDNA in PD cannot at this stage be ruled out and 
needs to be further investigated in a more critical and systematic way. Future studies should 
take into account limitations of past studies reviewed here to improve current study designs. 
Alternatively, they should consider the use of more standardised approaches such as the variant 
load approach. The limitations, challenges, and future prospects of studying mtDNA in PD are 
summarised in Supplementary Figure 1. Although not caveat-free, the study of mtDNA 
depletion appears most promising and we propose that further research in this area is required, 
particularly regarding the mechanisms and possible nDNA variation underlying mtDNA 
depletion in PD patients.  
Albeit small, relative to the nuclear genome, the mitochondrial genome is an integral 
component for the production and functioning of mitochondria, and overall eukaryotic cell 
homeostasis. The role of mtDNA therefore should not be underestimated, and future adequately 
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powered and well-designed studies exploring current (mtDNA variation and levels) and new 
avenues (including MDPs) are needed to fully assess the magnitude of its contribution to PD 
pathogenesis. 
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Figure Legends 
Figure 1. The mitochondrion and structure of human mitochondrial DNA 
A) Basic structure of a mitochondrion containing multiple copies of mitochondrial DNA 
(mtDNA) represented as black circles. B) Structure of mtDNA: a 16 569 bp circular, double-
stranded molecule consisting of a guanine-rich heavy strand (H-strand) and a light strand (L-
strand), rich in cytosine. Approximately 93% of the genome is coding, having only one 
significant non-coding control region which includes the displacement loop (D-loop). This 
stretch of DNA contains the origin of H-strand replication (OH) the H-strand transcriptional 
promoters (HSP1 and HSP2) as well as the L-strand promoter (LSP). The DNA 37 primarily 
contiguous genes, nine on the L-strand and 28 on the H-strand. Twenty-four genes encode 
mature RNA products: one 12 s rRNA (small ribosomal subunit) and one 16 s rRNA (large 
ribosomal subunit), and 22 mitochondrial tRNAs (genes highlighted in purple). The remaining 
13 mtDNA genes encode polypeptide components of the electron transport chain (ETC) 
involved in energy production via oxidative phosphorylation (OXPHOS). These include seven 
subunits (MT-ND1,2,3,4,4L,5,6) of complex I, one subunit (MT-CYB) of complex III, three 
subunits (MT-CO1,2, and 3) of complex IV, and two subunits (MT-ATP6 and 8) of complex 
V. mtDNA also encodes two mitochondrial-derived peptides, MOTS-c and Humanin, as short 
open reading frames (sORF) in the MT-RNR1 and MT-RNR2  genes respectively. Deletions in 
mtDNA frequently occur in the major arc (indicated by the dark grey line) between the heavy 
and light strand origins of replication (OH and OL respectively). Among these deletions is the 
‘common deletion’: a 4 977-base-pair deletion located between the MT-ATP8 and MT-ND5 
genes as indicated by the dark green arrows. 
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Table 1. Features of mitochondrial dysfunction observed in sporadic Parkinson’s disease 
cybrids  
ATP = Adenosine triphosphate; mtDNA = Mitochondrial DNA; ROS = reactive oxygen species 
 
 
 
 
 
 
 
 
 
Phenotype References 
Altered mitochondrial ultrastructure: e.g. rounded, swollen 
mitochondria; mitochondrial matrix with few or disrupted 
cristae; presence of intramitochondrial inclusions. 
[43, 161-163] 
Decreased complex I activity [42, 43, 163-165] 
Mitochondrial depolarisation [43] 
Reduced mitochondrial ability to buffer cytosolic calcium/ 
altered calcium homeostasis 
[166, 167] 
Reduced ATP levels [43, 163, 168] 
Apoptosis: altered levels of apoptosis-related proteins [43, 169, 170] 
Reduced mtDNA content [50, 171] 
Microtubule depolymerisation [163, 168] 
Increased alpha-synuclein oligomerization [163, 166, 168] 
Existence of fibrillar and vesicular inclusions (cybrid Lewy 
bodies) 
[163, 172] 
Reduced respiratory reserve capacity [165] 
Increased toxin susceptibility [42, 43] 
Significantly reduced mitochondrial axonal transport [171] 
Increased ROS production [42, 163] 
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Table 2. Summary of mtDNA haplogroup association studies in Parkinson’s disease 
Ethnicity (Ancestry) Study participants N Multiple-
Test 
Correction 
Estimates of 
statistical 
power 
determined 
Outcome/ Main findings  Reference 
American (European) Cases 609 NS NS Haplogroups J (P = 0,02) and K (P = 0,02) associated with reduced PD risk. 
SNP m.10398A>G was reported to be protective against PD (P = 0,0001). 
SNP m.9055G>A in MT-ATP6 reduced PD risk in women (P = 0,03). SNP 
m.13708G>A reduced PD risk in individuals > 70 years of age (P = 0,010). 
[73]  
Controls 340 
  
 
Irish (European) Cases 90 Yes 
(Bonferroni 
correction) 
NS No significant association between haplogroup J and PD found. SNP 
m.4216T>C, in linkage with mtDNA TJ cluster, was associated with 
increased PD risk (P = 0,014). 
[77] 
 
Controls 129 
  
 
Finnish (European) Cases (PD) 210 NS NS Supercluster JTWIX was associated with an increased risk of PD (P = 0,27) 
and PD with dementia (PDD) (P = 0,18). 
[78]  
Cases (PD) 28 
  
  
Controls 104 
  
 
Spanish from 
Asturias, Northern 
Spain (European) 
Cases 271 Yes 
(Bonferroni 
correction) 
NS No Haplogroups were associated with PD risk. SNP m.4336T>C associated 
with increased PD risk only in females (P = 0,011). SNP m.10398A>G was 
protective against PD (P = 0,009). 
[75] 
 
Controls 230 
  
 
English (European) Cases 455 NS NS Haplogroups J and K not significantly associated with reduced PD risk. UKJT 
cluster reduced PD risk (P < 0,0001). 
[72]  
Control group 1 269 
  
  
Control group 2 (Birth 
cohort) 
178 
  
 
 
Control group 3 (Post-
mortem brain tissue from 
AD patients) 
185 
  
 
Italian (European) Cases 620 NS NS Haplogroup K (P = 0,048) but not J associated with reduced PD risk. SNP 
m.10398A>G did not significantly alter PD risk. 
[68] 
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Control group 1 (CT1) 1486 
  
  
Control group 2 (CT2) 509 
  
 
Taiwanese (Asian) Cases 416  Yes 
(Bonferroni 
correction) 
NS No haplogroups associated with PD risk. [81] 
 
Controls 372 
  
 
Polish from central, 
south and north-
western Poland 
(European) 
Cases 241 NS Yes Haplogroup J (P = 0,0014) associated with reduced PD risk in males (after 
stratification by gender). Sub-lineages U4 +U5a1 + K+J1c + J2 also reduced 
PD risk (P = 0,027).  SNP m.10398A>G did not significantly alter PD risk. 
[66] 
 
Controls 277 
  
  
Cases for gender 
stratified haplogroup J 
analysis 
304 
  
 
 
Controls 316 
  
  
Additional cases for 
haplogroup K analysis 
91 
  
 
 
Additional controls for 
haplogroup K analysis 
137 
  
 
Greek from Crete 
(European) 
Cases 224 NS NS No haplogroups associated with PD risk. SNP m.10398A>G did not 
significantly alter PD risk. 
[76] 
 
Controls 383 
  
 
Russian, Tatar 
(European) 
Cases 157 NS NS Haplogroup H associated with an increased PD risk (P = 0,0001). UK cluster 
associated with a decreased PD risk (P = 0,003). 
[70] 
 
Controls 183 
  
 
Australian from New 
South Wales and 
Queensland 
(European) 
Cases 890 NS Yes No significant associations between PD risk and haplogroups J and K found, 
nor the pooled UJKT haplogroup cluster. 
[71]  
 
Controls 3491 
  
 
English (European) Cases (Discovery phase) 1719 NS Yes [69] 
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Controls (Discovery 
phase) 
2889 
  
Association study: No association between haplogroups and PD nor SNP 
m.10398A>G and PD. Super-haplogroup JT was associated with a protective 
effect against PD (P = 0,0354). Mitochondrial variants m.2158T>C 
(discovery: P = 0,024; replication: P = 0,0245) and m.11251A>G (discovery: 
P = 0,0292; replication: P = 0,0012) were associated with a reduced risk of 
PD in both the discovery and replication cohorts. Meta-analysis: 
Haplogroups J (P = 0,0122), K (P = 0,00363), T (P = 0,0245) and super-
haplogroup JT (P = 0,000584) associated with reduced PD risk. Increased PD 
risk was associated with cluster HV (P = 0,00364). 
 
 
Cases (Replication 
phase) 
851 
  
 
 
Controls (Replication 
phase) 
2717 
  
 
 
Cases (Meta-Analysis) 6140 
  
  
Controls (Meta-Analysis) 13280 
  
 
Spanish from 
Pamplona, North-East 
Spain (European) 
Cases 478 Yes (NS) NS No haplogroups were associated with PD risk [74] 
 
Controls 394  
Spanish from 
Santiago de 
Compostela, North-
West Spain 
(European) 
Cases 305  
 
Controls 293  
Han Chinese from 
Southern China 
(Asian) 
Cases (Total) 279 NS NS Overall, no association between haplogroups and PD. Haplogroup B (P = 
0,004) associated with a lower risk for EOPD in individuals younger than 50 
years (after age stratification,).  Haplogroup D associated with a higher risk 
of PD (P = 0,033) and Haplogroup B was associated with a lower risk of PD 
(P = 0,018) in individuals younger than 50. 
[82] 
 
EOPD (<50) 63 
  
  
LOPD (>50) 216 
  
  
Controls (Total) 510 
  
  
Control Team 1 118 
  
  
Controls 332 
  
 
Han Chinese from 
Northern China 
(Asian) 
Cases 322 Yes 
(Bonferroni 
correction) 
NS SNP m.10398A>G (P = 0,001) significantly associated with increased PD risk 
in females (P = 0,0036). 
[173] 
Taiwanese (Asian) Cases 725 Yes 
(Bonferroni 
correction) 
NS Haplogroup B5 associated with a reduced PD risk (P = 0,002). [80] 
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Controls 744 
  
 
Greek from Cypriot 
(European) 
Cases 230 Yes 
(Bonferroni 
correction) 
NS Haplogroup U associated with reduced PD risk (P =0,03), supercluster LMN 
(P = 0,01) and cluster N(xR) (P = 0,006) were significantly protective against 
PD in females. 
 
[67] 
 
Controls 457 
  
 
Han Chinese from 
East China (Asian) 
Cases 500 NS NS D-loop-sequencing: SNPs m.151T>C (P = 0,023), m.189G>A (P = 0,03), 
m.16086C>T (P = 0,007 and m.16271C>T (P = 0,0497) were associated with 
increased PD risk. SNPs m.318C>T and m.16134T>C (P = 0,022) were 
associated with decreased PD risk. Haplogroup A5 (P = 0,039) was associated 
with increased PD risk. Haplogroup B5 (P = 0,068) was associated with a 
reduced disease risk.  Meta-analysis: Haplogroup B5, but not B4, was 
protective against PD (P = 0,0003). Haplogroup G not associated with PD (P 
= 0,09). 
[79] 
 
Controls 505 
  
 
AD = Alzheimer’s disease; EOPD = Early onset Parkinson’s disease; LOPD = Late onset Parkinson’s disease; mtDNA = Mitochondrial DNA; N = sample size; NA = Not Applicable; NS = 
Not specified; PDD = Parkinson’s disease with dementia; PD = Parkinson’s disease 
 
 
 
 
 
 
 
 
45 
 
Table 3. Summary of mtDNA sequencing studies on somatic variation in Parkinson’s disease 
Study participants N Brain region Variants 
considered 
Pathogenicity 
Scoring 
Method  mtDNA region 
sequenced 
Outcome/ Main findings Reference 
Cases 8 FCtx (Tissue 
homogenate) 
All point 
mutations; G:C to 
T:A and T:A to 
G:C transversions 
NS PCR-cloning-
sequencing 
strategy  
MT-ND4 No significant difference in 
heteroplasmic point mutation 
burdens between cases and 
controls. 
[97] 
Controls (< 10 years old)  2 
     
 
Controls (12-24 years 
old) 
6 
     
 
Controls (Elderly) 7 
     
 
Cases 8 SN (Tissue homogenate) 
  
 
Controls (< 10 years old)  3 
     
 
Controls (12-24 years 
old) 
4 
     
 
Controls (Elderly) 10 
     
 
Cases 6 FCtx (Tissue 
homogenate) 
Nonsynonymous 
point mutations 
Yes PCR-cloning-
sequencing 
strategy  
MT-ND1; MT-
ND2; MT-ND3; 
MT-ND4L; MT-
ND4; MT-ND5; 
MT-ND6 
No significant difference in 
heteroplasmic point mutation 
burdens between cases and 
controls. 
[51] 
Controls 6 
    
 
Cases (Early PD + 
ILBD) 
9 SN (Isolated 
dopaminergic 
neurons; Glial 
cells) 
All point 
mutations; GT/CA 
transversions 
NS PCR-cloning-
sequencing 
strategy 
MT-ND5; D-loop Significantly elevated levels of 
heteroplasmic point mutations in 
neurons of early PD + ILBD 
cases compared to controls (P < 
0,0001) and late stage PD cases 
(P = 0,0006). No significant 
difference in mtDNA point 
mutation levels in SN glia from 
early PD + ILBD cases 
compared to controls (P = 0,73). 
[95] 
Cases (Late PD) 8 
     
 
Controls 23 
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Cases 114 SN (Tissue 
homogenate) 
All point 
mutations; 
nonsynonymous 
point mutations  
Yes (MutPred 
scoring) 
NGS (Illumina 
sequencing) 
Whole mtDNA Significantly higher 
heteroplasmic variant burden in 
the SN (P = 0,012) and FCtx (P = 
0,005) of PD patients compared 
to controls. 
[94] 
Controls 34 
     
  
Cases 125 FCtx (Tissue homogenate) 
  
  
Controls 30 
     
  
Cases 10 SNpc (Single 
dopaminergic 
neurons- 184 in 
total) 
SNVs; transitions 
and transversions; 
deletions 
NS Ultra-deep NGS 
(Illumina 
sequencing) 
Two rRNA (MT-
RNR1, MT-
RNR2); 10 tRNA 
(MT-TV, MT-
TL1, MT- TI, MT-
TQ, MT-TM, MT-
TW, MT-TA, MT-
TN, MT-TC, MT-
TY); two 
Complex I genes 
(MT-ND1, MT-
ND2)  
Significantly higher levels of 
mtDNA deletions (P = 0,004), 
but not point mutations, in 
patients compared to controls. 
Significant mtDNA depletion in 
PD cases compared to controls (P 
= 0,006). 
[96] 
Controls 10  
    
 
Cases (DLB-PD) 89 Cerebellum; 
Cerebral 
Cortex; Other 
brain regions 
(Tissue 
homogenate) 
All point 
mutations; 
nonsynonymous 
point mutations  
Yes (MutPred 
and Polyphen-
2) 
NGS (Illumina 
sequencing)  
Whole mtDNA 
(Extracted from 
whole exome 
sequencing data) 
No significant difference in 
heteroplasmic point mutation 
burdens between cases and 
controls. 
[98] 
Controls 351 
     
  
Controls (Young) 110 
     
 
         
DLB-PD = Dementia with Lewy Bodies or Parkinson's Disease; FCtx = Frontal cortex; ILBD = Incidental Lewy body disease; mtDNA = Mitochondrial DNA; N = Sample 
size; NA = Not applicable; NGS = Next Generation Sequencing; NS = Not specified; SN = Substantia Nigra; SNVs = Single nucleotide variants; PD = Parkinson’s disease 
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